Federal Capture Intelligence

Research and Development in Biotechnology (except Nanobiotechnology) contractors at the Department of Health and Human Services

Contract actions: October 1, 2021 – July 27, 2026 Updated July 28, 2026 Department of Health and Human Services agency guide NAICS 541714 · Research and Development in Biotechnology (except Nanobiotechnology)
Latest 12 months
$1.4B
Net obligations · Up $11.9M vs. $1.4B preceding
Prime contractors
210
With positive obligations in the latest 12 months

Market snapshot for Research and Development in Biotechnology (except Nanobiotechnology) at the Department of Health and Human Services

Federal records show $11.6B in net obligations across 1,689 awards in Research and Development in Biotechnology (except Nanobiotechnology) at the Department of Health and Human Services from Oct 1, 2021 through Jul 27, 2026. This market accounts for 8.2% of $140.6B in agency-wide net prime contract obligations over the period shown. Latest 12-month net obligations increased 0.9% from $1.4B to $1.4B. 26 prime contractors accounted for at least 80% of positive obligations in that latest period.

Fiscal-year activity

FY26 is year-to-date through Jul 27, 2026; earlier years show complete fiscal-year totals.

FY26 year-to-date: $845.6M versus $448.3M through the same date in FY25 (+88.6%).
Net obligations · complete fiscal yearNet obligations · FY26 YTDContract actions
View fiscal-year data table
Fiscal yearNet obligationsContract actionsCoverage
FY2022$2.0B1,024Complete
FY2023$4.5B1,109Complete
FY2024$3.2B1,261Complete
FY2025$1.0B1,163Complete
FY2026$845.6M600YTD through Jul 27, 2026

Market at a glance

All reported prime contract awards
All-period net obligations
$11.6B
1,689 awards · 682 prime contractors
Latest 12-month movement
+0.9%
$1.4B vs. $1.4B
Leading eight prime share
52.1%
Share held by the eight leading prime contractors in the latest 12 months
View agency share, denominators, and set-aside reporting
Agency context
8.2% of $140.6B in agency-wide net obligations.
Set-aside share when reported
11.3% of 1,152 awards with reported set-aside status.
Set-aside reporting
130 set aside · 1,022 no set-aside · 537 not reported

What changed in the last 12 months?

Jul 28, 2025–Jul 27, 2026, compared with Jul 28, 2024–Jul 27, 2025.

Competitive shifts

MELINTA THERAPEUTICS, LLC climbed the most in the contractor rankings
#55→#18Up 37 places
The contractor accounts for 1.5% of positive obligations across 2 reported actions.
19 contractors were first observed in this market during the latest 12 months
$93.4MLatest 12-month obligations
Contractor-level obligations and first-observed dates appear below. “First observed” applies only to this market and the period shown.
View 19 contractors
ContractorLatest 12 months
CIDARA THERAPEUTICS INC was the largest newly observed contractor
$58.1MLatest 12-month obligations
First observed in this market on Sep 30, 2025, the contractor now ranks #5 by positive obligations across 2 reported actions.

Market structure

Top-five contractor share increased
30.7%→42.5%+11.8 percentage points
Contractors outside the top five now account for 57.5% of positive obligations.

Award activity

View 5 additional material changes

Buyer demand

Reported obligations through BARDA - ASPR / DAAPPO / BARDA DCMA decreased
$1.2B→$1.1B−$94.5M
Latest-period activity spans 166 awards across 105 prime contractors.

Competitive shifts

4J THERAPEUTICS INC fell the most in the contractor rankings
#10→#210Down 200 places
The latest position is based on 1 reported action.
SIGA TECHNOLOGIES, INC. had no reported activity in the latest 12 months
$53.1M→$0No latest-period activity
It previously ranked #5 by positive obligations, based on 3 reported actions.
MONOGRAM BIOSCIENCES, INC. recorded the largest net deobligation
$0→−$15.6M−$15.6M
The contractor now is unranked by positive obligations, based on 3 reported actions.
How these findings are calculated

Findings are selected from matched-period changes in obligations, share, rank, funding offices, concentration, reported set-asides, material award actions, and agency-peer outliers. Related signals are combined, and only material evidence-backed changes are shown. Review the full methodology.

Funding pattern for Research and Development in Biotechnology (except Nanobiotechnology) at the Department of Health and Human Services

See how positive obligations were attributed across funding offices in the 12 months ending Jul 27, 2026.

78.4% of positive obligations were attributed to BARDA - ASPR / DAAPPO / BARDA DCMA. That represents $1.1B, down $94.5M from the preceding 12 months.

Latest 12-month share of positive obligations; the gray segment represents all other reported offices.

  1. BARDA - ASPR / DAAPPO / BARDA DCMA78.4% · $1.1B · down $94.5M
  2. NATIONAL INSTITUTES OF HEALTH NIAID11.6% · $162.3M · down $59.5M
  3. OFC ASST SEC FOR PREPARENESS RES2.0% · $27.9M · down $14.2M
  4. NATIONAL INSTITUTES OF HEALTH NIDA1.8% · $25.2M · down $16.5M
  5. NATIONAL INSTITUTES OF HEALTH NINDS1.7% · $24.4M · up $2.8M
  6. All other reported offices4.5% of positive obligations
View reported office rankings, comparisons, and evidence

USAspending assigns each award to a funding office. That office may differ from the requiring activity, program office, contracting office, individual buyer, or actual customer.

  1. Reported funding office

    BARDA - ASPR / DAAPPO / BARDA DCMA

    #1Rank unchanged

    Latest 12 months

    $1.1B

    78.4% of positive obligations

    Versus preceding 12 months

    −$94.5M

    105 active prime contractors · 166 awards

    View office comparison and evidence

    Reported obligations decreased 7.9% from $1.2B to $1.1B. The office’s share of positive obligations moved from 75.1% to 78.4%, a change of +3.3 percentage points.

    The latest period contains 264 actions across 166 awards and 20 newly active prime contractors. The preceding period contained 117 active prime contractors and 169 awards.

    Leading award-level changes

  2. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NIAID

    #2Rank unchanged

    Latest 12 months

    $162.3M

    11.6% of positive obligations

    Versus preceding 12 months

    −$59.5M

    83 active prime contractors · 140 awards

    View office comparison and evidence

    Reported obligations decreased 26.8% from $221.8M to $162.3M. The office’s share of positive obligations moved from 13.9% to 11.6%, a change of −2.4 percentage points.

    The latest period contains 214 actions across 140 awards and 22 newly active prime contractors. The preceding period contained 88 active prime contractors and 165 awards.

  3. Reported funding office

    OFC ASST SEC FOR PREPARENESS RES

    #3Rank unchanged

    Latest 12 months

    $27.9M

    2.0% of positive obligations

    Versus preceding 12 months

    −$14.2M

    11 active prime contractors · 14 awards

    View office comparison and evidence

    Reported obligations decreased 33.8% from $42.1M to $27.9M. The office’s share of positive obligations moved from 2.6% to 2.0%, a change of −0.7 percentage points.

    The latest period contains 19 actions across 14 awards and 7 newly active prime contractors. The preceding period contained 20 active prime contractors and 21 awards.

  4. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NIDA

    #4Rank unchanged

    Latest 12 months

    $25.2M

    1.8% of positive obligations

    Versus preceding 12 months

    −$16.5M

    21 active prime contractors · 33 awards

    View office comparison and evidence

    Reported obligations decreased 39.5% from $41.6M to $25.2M. The office’s share of positive obligations moved from 2.6% to 1.8%, a change of −0.8 percentage points.

    The latest period contains 51 actions across 33 awards and 10 newly active prime contractors. The preceding period contained 25 active prime contractors and 30 awards.

  5. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NINDS

    #5Up 1 from #6

    Latest 12 months

    $24.4M

    1.7% of positive obligations

    Versus preceding 12 months

    +$2.8M

    2 active prime contractors · 2 awards

    View office comparison and evidence

    Reported obligations increased 12.9% from $21.6M to $24.4M. The office’s share of positive obligations moved from 1.4% to 1.7%, a change of +0.4 percentage points.

    The latest period contains 3 actions across 2 awards. The preceding period contained 8 active prime contractors and 21 awards.

  6. Reported funding office

    FDA OFFICE OF ACQ GRANT SVCS

    #6Down 1 from #5

    Latest 12 months

    $18.2M

    1.3% of positive obligations

    Versus preceding 12 months

    −$8.7M

    58 active prime contractors · 77 awards

    View office comparison and evidence

    Reported obligations decreased 32.4% from $26.9M to $18.2M. The office’s share of positive obligations moved from 1.7% to 1.3%, a change of −0.4 percentage points.

    The latest period contains 105 actions across 77 awards and 20 newly active prime contractors. The preceding period contained 66 active prime contractors and 86 awards.

  7. Reported funding office

    NATIONAL INSTITUTES OF HEALTH

    #7Rank unchanged

    Latest 12 months

    $10.7M

    0.76% of positive obligations

    Versus preceding 12 months

    −$5.6M

    1 active prime contractor · 1 award

    View office comparison and evidence

    Reported obligations decreased 34.4% from $16.3M to $10.7M. The office’s share of positive obligations moved from 1.0% to 0.76%, a change of −0.3 percentage points.

    The latest period contains 1 action across 1 award and 1 newly active prime contractor. The preceding period contained 4 active prime contractors and 6 awards.

  8. Reported funding office

    ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)

    #8New to the positive-obligation ranking

    Latest 12 months

    $8.6M

    0.61% of positive obligations

    Versus preceding 12 months

    +$8.6M

    7 active prime contractors · 7 awards

    View office comparison and evidence

    Reported obligations rose from $0 to $8.6M. The office’s share of positive obligations moved from 0% to 0.61%, a change of +0.6 percentage points.

    The latest period contains 19 actions across 7 awards and 7 newly active prime contractors. The preceding period contained 0 active prime contractors and 0 awards.

  9. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NICHD

    #9Up 3 from #12

    Latest 12 months

    $8.0M

    0.57% of positive obligations

    Versus preceding 12 months

    +$5.1M

    24 active prime contractors · 52 awards

    View office comparison and evidence

    Reported obligations increased 179.1% from $2.8M to $8.0M. The office’s share of positive obligations moved from 0.18% to 0.57%, a change of +0.4 percentage points.

    The latest period contains 102 actions across 52 awards and 4 newly active prime contractors. The preceding period contained 24 active prime contractors and 58 awards.

  10. Reported funding office

    CDC OFFICE OF ACQUISITION SERVICES

    #10Down 2 from #8

    Latest 12 months

    $6.4M

    0.46% of positive obligations

    Versus preceding 12 months

    −$936K

    12 active prime contractors · 12 awards

    View office comparison and evidence

    Reported obligations decreased 12.7% from $7.3M to $6.4M. The office’s share of positive obligations moved from 0.46% to 0.46%, a change of 0.0 percentage points.

    The latest period contains 13 actions across 12 awards and 4 newly active prime contractors. The preceding period contained 24 active prime contractors and 31 awards.

  11. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NHLBI

    #11Down 1 from #10

    Latest 12 months

    $4.6M

    0.33% of positive obligations

    Versus preceding 12 months

    +$1.1M

    18 active prime contractors · 27 awards

    View office comparison and evidence

    Reported obligations increased 32.2% from $3.5M to $4.6M. The office’s share of positive obligations moved from 0.22% to 0.33%, a change of +0.1 percentage points.

    The latest period contains 30 actions across 27 awards and 12 newly active prime contractors. The preceding period contained 25 active prime contractors and 38 awards.

  12. Reported funding office

    ASPR BARDA DIV CONTRACTS MGMT & ACQ

    No positive-obligation rank

    Latest 12 months

    $0

    0% of positive obligations

    Versus preceding 12 months

    +$200.0M

    0 active prime contractors · 0 awards

    View office comparison and evidence

    Reported obligations moved from $200.0M in net deobligations to $0 in net obligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.

    The latest period contains 0 actions across 0 awards. The preceding period contained 1 active prime contractor and 1 award.

    Leading award-level changes

How this work is bought

Reported award structure, competition, pricing, work categories, and contracting channels for Research and Development in Biotechnology (except Nanobiotechnology) at the Department of Health and Human Services.

During Jul 28, 2025–Jul 27, 2026, this market recorded $1.5B in positive net award obligations across 317 awards. The leading reported procedure, Negotiated Proposal/Quote, accounted for 94.5% of that positive-obligation base. Awards with a reported parent IDV accounted for 16.8%.

Leading award type
83.0%
Definitive Contract
Leading reported procedure
94.5%
Negotiated Proposal/Quote
Reported parent IDV
16.8%
of positive obligations had a reported parent IDV
Median reported offers
1
231 of 317 awards reported offers

Buying method changes

Compared with Jul 28, 2024–Jul 27, 2025. Based on 317 current awards and 437 preceding awards with positive net obligations.

Median positive award obligations
$600K
Up from $260K in the preceding period
Parent-IDV obligation share
16.8%
Down from 35.2% in the preceding period
How to read these changes

Directional color and the Up or Down labels show historical movement only. Green does not mean favorable and red does not mean unfavorable; neither predicts a future procurement method.

Same-NAICS comparison

Compared with the NAICS 541714 peer median, parent-IDV obligation share is 41.5 percentage points lower, reported full-and-open obligation share is 84.9 percentage points higher, delivery-order obligation share is 41.5 percentage points lower, and median positive award obligations are 1597.2% higher.

MeasureThis marketPeer medianDifference
Parent-IDV obligation share16.8%58.3%-41.5 pts
Reported full-and-open obligation share93.3%8.4%+84.9 pts
Delivery-order obligation share16.8%58.3%-41.5 pts
Median positive award obligations$600K$35K+1597.2%
Peer cohort and comparison limits

The peer median gives each of the 3 eligible agency markets equal weight. The included agency markets are:

Agency mission, scale, and acquisition context can differ. Peer position does not establish market attractiveness or predict a future procurement method.

View buying-method details and data coverage

Award types

Reported valueAwardsPositive obligationsShare
Definitive Contract(D)130$1.2B83.0%
Delivery Order(C)126$248.4M16.8%
Purchase Order(B)53$2.8M0.19%
BPA Call(A)8$182K0.010%

Reported parent-award types

Reported valueAwardsPositive obligationsShare
IDC(B)125$248.2M16.8%
BPA(E)8$182K0.010%
FSS(C)1$155K0.010%
Not reported183$1.2B83.2%

Single- or multiple-award parent structure

Reported valueAwardsPositive obligationsShare
Single Award(S)94$227.0M15.3%
Multiple Award(M)40$21.6M1.5%
Not reported183$1.2B83.2%

Solicitation procedures

Reported valueAwardsPositive obligationsShare
Negotiated Proposal/Quote(NP)196$1.4B94.5%
Only One Source(SSS)8$41.6M2.8%
Subject To Multiple Award Fair Opportunity(MAFO)40$21.6M1.5%
Basic Research(BR)9$9.8M0.67%
Simplified Acquisition(SP1)61$7.7M0.52%
Two Step(TS)3$862K0.060%

Extent competed

Reported valueAwardsPositive obligationsShare
Full And Open Competition(A)224$1.4B93.3%
Full And Open Competition After Exclusion Of Sources(D)24$49.6M3.4%
Not Competed(C)8$41.6M2.8%
Competed Under SAP(F)22$5.9M0.40%
Not Competed Under SAP(G)39$1.8M0.12%

Fair-opportunity and limited-source reporting

Reported valueAwardsPositive obligationsShare
Fair Opportunity Given(FAIR)36$20.1M1.4%
Only One Source - Other(ONE)3$1.4M0.090%
Follow-On Action Following Competitive Initial Action(FOO)1$59K0%
Not reported277$1.5B98.5%

Other-than-full-and-open reasons

Reported valueAwardsPositive obligationsShare
Only One Source-Other (FAR 6.302-1 Other)(ONE)7$22.1M1.5%
Unique Source (FAR 6.302-1(B)(1))(UNQ)1$19.5M1.3%
SAP Non-Competition (FAR 13)(SP2)32$1.7M0.11%
Authorized By Statute (FAR 6.302-5(A)(2)(I))(OTH)7$162K0.010%
Not reported270$1.4B97.1%

Contract pricing types

Reported valueAwardsPositive obligationsShare
Cost Plus Fixed Fee(U)84$773.2M52.3%
Firm Fixed Price(J)139$399.0M27.0%
Cost Sharing(T)11$168.4M11.4%
Cost No Fee(S)80$135.1M9.1%
Labor Hours(Z)2$3.7M0.25%
Cost Plus Award Fee(R)1$38K0%

Product or Service Codes

Reported valueAwardsPositive obligationsShare
Health R&d Services; Health Care Services; Experimental Development(AN13)45$422.9M28.6%
Drugs And Biologicals(6505)16$278.8M18.9%
Health R&d Services; Health Care - Other; Applied Research(AN42)18$248.4M16.8%
Health R&d Services; Health Care Services; Applied Research(AN12)95$177.7M12.0%
Health R&d Services; Health Care Services; Basic Research(AN11)62$110.5M7.5%
Health R&d Services; Health Care Services; R&d Administrative Expenses(AN14)3$61.6M4.2%
Other reported values78$179.5M12.1%

Awarding subagencies

Reported valueAwardsPositive obligationsShare
Office of Assistant Secretary for Preparedness and Response(7505)77$1.2B80.2%
National Institutes of Health(7529)186$253.2M17.1%
Food and Drug Administration(7524)34$23.9M1.6%
Departmental Offices(1406)9$8.7M0.59%
Centers for Disease Control and Prevention(7523)10$6.5M0.44%
Indian Health Service(7527)1$155K0.010%

Awarding offices

Reported valueAwardsPositive obligationsShare
Barda - Aspr / Daappo / Barda Dcma(75A501)77$1.2B80.2%
National Institutes Of Health Niaid(75N930)76$165.6M11.2%
National Institutes Of Health Nida(75N950)16$65.3M4.4%
Fda Office Of Acq Grant Svcs(75F401)34$23.9M1.6%
National Institutes Of Health Nichd(75N940)44$10.2M0.69%
Ibc Acq Svcs Directorate (00004)(140D04)9$8.7M0.59%
Other reported values61$18.8M1.3%

Reported parent IDVs

Reported valueAwardsPositive obligationsShare
75A50122D00003(7505)4$30.3M2.0%
75N93021D00035(7529)2$28.2M1.9%
75A50122D00017(7505)8$26.8M1.8%
75N95024D00038(7529)1$24.3M1.6%
75A50123D00005(7505)2$23.0M1.6%
75N93021D00038(7529)3$21.9M1.5%
75A50122D00007(7505)4$11.4M0.77%
75N95023D00006(7529)1$7.4M0.50%
Other reported values109$75.2M5.1%
Not reported183$1.2B83.2%

Exactly matched vehicle usage

19 awards matched an unambiguous catalog vehicle PIID. Company membership is not used as evidence of award-channel usage.

Offers, award size, and timing

Median reported offers
1 median
231 reported · 86 not reported
Positive award obligations
$600K median
$57K–$2.3M middle 50%
Reported performance period
882 days (~2.4 years) median
317 reported · 0 not reported

Calculations group latest-period actions by award, retain awards with positive net obligations for share denominators, and use each award's latest reported USAspending procurement fields as of Jul 27, 2026. Blank competition, pricing, PSC, or parent-IDV values remain not reported; they are not inferred. Offer counts must be positive and below the FPDS 999 placeholder. Awarding organizations can differ from the funding agency that defines this page.

Prime contractors for Research and Development in Biotechnology (except Nanobiotechnology) at the Department of Health and Human Services

Latest 12-month concentration and complete prime contractor rankings across the period shown.

Prime contractor concentration
26 of 210prime contractors account for at least 80% of positive obligations in the last 12 months
Largest prime contractor
18.2%of positive obligations in the last 12 months
Leading four prime contractors
38.5%of positive obligations in the last 12 months
Leading eight prime contractors
52.1%of positive obligations in the last 12 months

Based on $1.5B in positive obligations during the 12 months ending Jul 27, 2026. Individual shares and movement appear in the searchable rankings below. Movement compares with Jul 28, 2024–Jul 27, 2025.

Last 12mo obligation volume: Highest positive obligations first; net deobligations follow by magnitude; contractors with no activity in the last 12 months follow by all-period obligations. Ranks use the complete contractor list and remain fixed when search narrows the results.

15 leading contractors
  1. #1

    Last 12mo obligations

    $266.8M

    18.2%

    Dollar movement

    +$218.0M

    vs. prior 12 months

    Last 12mo awards

    3 awards

    4 actions

    Historical and award details for ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)
    Obligations: prior → latest
    $48.7M → $266.8M
    +447.5%
    Share: prior → latest
    3.2% → 18.2%
    +15.0 percentage points
    All-period obligations
    $458.8M
    4.0% of all-period positive obligations · 3 awards
    Recorded activity
    Since Nov 4, 2021
    through May 11, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside32
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  2. #2

    Last 12mo obligations

    $119.2M

    8.2%

    Dollar movement

    +$119.2M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for SHIONOGI INC
    Obligations: prior → latest
    $0 → $119.2M
    Not comparable
    Share: prior → latest
    0% → 8.2%
    +8.2 percentage points
    All-period obligations
    $119.2M
    1.0% of all-period positive obligations · 1 award
    Recorded activity
    Since Apr 6, 2026
    through Apr 6, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  3. #3

    Last 12mo obligations

    $117.5M

    8.0%

    Dollar movement

    +$84.6M

    vs. prior 12 months

    Last 12mo awards

    1 award

    4 actions

    Historical and award details for START2 GROUP, INC.
    Obligations: prior → latest
    $32.9M → $117.5M
    +257.5%
    Share: prior → latest
    2.2% → 8.0%
    +5.9 percentage points
    All-period obligations
    $151.9M
    1.3% of all-period positive obligations · 1 award
    Recorded activity
    Since Apr 9, 2024
    through Jul 16, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business11
    All-period set-aside types

    None reported.

  4. #4

    Last 12mo obligations

    $60.0M

    4.1%

    Dollar movement

    −$159.2M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for AMGEN USA INC
    Obligations: prior → latest
    $219.2M → $60.0M
    −72.6%
    Share: prior → latest
    14.4% → 4.1%
    −10.3 percentage points
    All-period obligations
    $774.7M
    6.7% of all-period positive obligations · 2 awards
    Recorded activity
    Since Sep 28, 2022
    through Mar 6, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside12
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  5. #5

    Last 12mo obligations

    $58.1M

    4.0%

    Dollar movement

    +$58.1M

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for CIDARA THERAPEUTICS INC
    Obligations: prior → latest
    $0 → $58.1M
    Not comparable
    Share: prior → latest
    0% → 4.0%
    +4.0 percentage points
    All-period obligations
    $58.1M
    0.50% of all-period positive obligations · 1 award
    Recorded activity
    Since Sep 30, 2025
    through Jun 2, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business10
    All-period set-aside types

    None reported.

  6. #6

    Last 12mo obligations

    $52.9M

    3.6%

    Dollar movement

    +$45.4M

    vs. prior 12 months

    Last 12mo awards

    1 award

    3 actions

    Historical and award details for PUBLIC HEALTH VACCINES LLC
    Obligations: prior → latest
    $7.5M → $52.9M
    +606.7%
    Share: prior → latest
    0.49% → 3.6%
    +3.1 percentage points
    All-period obligations
    $66.7M
    0.57% of all-period positive obligations · 1 award
    Recorded activity
    Since Nov 2, 2021
    through Jun 8, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business11
    All-period set-aside types

    None reported.

  7. #7

    Last 12mo obligations

    $44.2M

    3.0%

    Dollar movement

    +$17.3M

    vs. prior 12 months

    Last 12mo awards

    20 awards

    41 actions

    Historical and award details for BATTELLE MEMORIAL INSTITUTE
    Obligations: prior → latest
    $26.9M → $44.2M
    +64.6%
    Share: prior → latest
    1.8% → 3.0%
    +1.3 percentage points
    All-period obligations
    $92.5M
    0.80% of all-period positive obligations · 27 awards
    Recorded activity
    Since Sep 23, 2022
    through Jul 17, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside01
    Not reported2013
    Reported small business00
    All-period set-aside types

    None reported.

  8. #8

    Last 12mo obligations

    $44.1M

    3.0%

    Dollar movement

    −$23.6M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    5 actions

    Historical and award details for BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL
    Obligations: prior → latest
    $67.8M → $44.1M
    −34.9%
    Share: prior → latest
    4.5% → 3.0%
    −1.4 percentage points
    All-period obligations
    $111.9M
    0.96% of all-period positive obligations · 2 awards
    Recorded activity
    Since Sep 18, 2024
    through May 27, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside21
    Not reported00
    Reported small business10
    All-period set-aside types

    None reported.

  9. #9

    Last 12mo obligations

    $34.9M

    2.4%

    Dollar movement

    +$34.9M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for VERICEL CORPORATION
    Obligations: prior → latest
    $0 → $34.9M
    Not comparable
    Share: prior → latest
    0% → 2.4%
    +2.4 percentage points
    All-period obligations
    $34.9M
    0.30% of all-period positive obligations · 1 award
    Recorded activity
    Since Apr 1, 2026
    through Apr 1, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business10
    All-period set-aside types

    None reported.

  10. #10

    Last 12mo obligations

    $33.2M

    2.3%

    Dollar movement

    +$1.1M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for CERUS CORPORATION
    Obligations: prior → latest
    $32.1M → $33.2M
    +3.5%
    Share: prior → latest
    2.1% → 2.3%
    +0.1 percentage points
    All-period obligations
    $65.4M
    0.56% of all-period positive obligations · 1 award
    Recorded activity
    Since Sep 20, 2024
    through Jul 21, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business11
    All-period set-aside types

    None reported.

  11. #11

    Last 12mo obligations

    $31.7M

    2.2%

    Dollar movement

    +$31.7M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for SPECTRAL MD, INC.
    Obligations: prior → latest
    $0 → $31.7M
    Not comparable
    Share: prior → latest
    0% → 2.2%
    +2.2 percentage points
    All-period obligations
    $86.6M
    0.75% of all-period positive obligations · 1 award
    Recorded activity
    Since Sep 27, 2023
    through Mar 18, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business10
    All-period set-aside types

    None reported.

  12. #12

    Last 12mo obligations

    $31.1M

    2.1%

    Dollar movement

    +$18.4M

    vs. prior 12 months

    Last 12mo awards

    5 awards

    9 actions

    Historical and award details for PPD DEVELOPMENT LP
    Obligations: prior → latest
    $12.8M → $31.1M
    +144.0%
    Share: prior → latest
    0.84% → 2.1%
    +1.3 percentage points
    All-period obligations
    $330.2M
    2.8% of all-period positive obligations · 10 awards
    Recorded activity
    Since Oct 28, 2021
    through Jul 10, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside33
    Not reported24
    Reported small business00
    All-period set-aside types

    None reported.

  13. #13

    Last 12mo obligations

    $26.4M

    1.8%

    Dollar movement

    +$8.9M

    vs. prior 12 months

    Last 12mo awards

    13 awards

    16 actions

    Historical and award details for SANOFI VACCINES US INC.
    Obligations: prior → latest
    $17.5M → $26.4M
    +50.7%
    Share: prior → latest
    1.2% → 1.8%
    +0.7 percentage points
    All-period obligations
    $69.0M
    0.59% of all-period positive obligations · 13 awards
    Recorded activity
    Since Feb 22, 2022
    through May 8, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported136
    Reported small business00
    All-period set-aside types

    None reported.

  14. #14

    Last 12mo obligations

    $25.9M

    1.8%

    Dollar movement

    +$19.0M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    5 actions

    Historical and award details for LOCUS BIOSCIENCES INC
    Obligations: prior → latest
    $6.9M → $25.9M
    +273.2%
    Share: prior → latest
    0.46% → 1.8%
    +1.3 percentage points
    All-period obligations
    $70.8M
    0.61% of all-period positive obligations · 2 awards
    Recorded activity
    Since Nov 2, 2021
    through Jul 7, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside21
    Not reported00
    Reported small business10
    All-period set-aside types

    None reported.

  15. #15

    Last 12mo obligations

    $24.3M

    1.7%

    Dollar movement

    +$12.5M

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for PSYCHOGENICS INC.
    Obligations: prior → latest
    $11.8M → $24.3M
    +106.1%
    Share: prior → latest
    0.78% → 1.7%
    +0.9 percentage points
    All-period obligations
    $36.0M
    0.31% of all-period positive obligations · 1 award
    Recorded activity
    Since Sep 6, 2024
    through May 27, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported11
    Reported small business11
    All-period set-aside types

    None reported.

Recompete watch for Research and Development in Biotechnology (except Nanobiotechnology) at the Department of Health and Human Services

Investigate potential recompetes surfaced by near-term end dates, award value, and recent contract changes.

ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.

CLINICAL TRIAL PLANNING AND EXECUTION (CTPE) H5 FLU

The reported potential end date is Jul 31, 2026. Current award value is 98.8% of reported potential value ($34.1M of $34.5M).

Performance period

99.6%

As of Jul 27, 2026Potential end Jul 31, 2026

Current award value as a share of potential value

98.8%

$34.1M current$34.5M potential
Supporting data

Reported performance starts Sep 27, 2023.

No later potential end date is reported; current and potential end dates are both Jul 31, 2026.

$34.1M is obligated against $34.1M in current reported award value (100.0%).

Reported potential end dates: Dec 1, 2025 → Mar 30, 2026 → Jul 31, 2026.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50123F33007

ARCTURUS THERAPEUTICS, INC.

PROCURE A PANDEMIC INFLUENZA VACCINE (PANDFLU) AND A QUADRIVALENT SEASONAL INFLUENZA VACCINE (QSFLU)

The reported potential end date is Aug 20, 2026. Current award value is 100.0% of reported potential value ($63.2M of $63.2M).

Performance period

98.3%

As of Jul 27, 2026Potential end Aug 20, 2026

Current award value as a share of potential value

100.0%

$63.2M current$63.2M potential
Supporting data

Reported performance starts Sep 1, 2022.

No later potential end date is reported; current and potential end dates are both Aug 20, 2026.

$63.2M is obligated against $63.2M in current reported award value (100.0%).

Reported potential end dates: Aug 31, 2025 → May 5, 2026 → Aug 20, 2026.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50122C00007

SEATTLE CHILDREN'S HOSPITAL

IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CONSORTIUM AND EOI::EO: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING

$86.6M is obligated on an award with a reported potential end date of March 31, 2027.

Performance period

91.0%

As of Jul 27, 2026Potential end Mar 31, 2027

Current award value as a share of potential value

100.0%

$86.6M current$86.6M potential
Supporting data

Reported performance starts Sep 30, 2019.

No later potential end date is reported; current and potential end dates are both Mar 31, 2027.

$86.6M is obligated against $86.6M in current reported award value (100.0%).

Reported potential end dates: Sep 29, 2026 → Mar 31, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75N93019C00070

RHO FEDERAL SYSTEMS DIVISION INC

EO14398; AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)

$40.1M is obligated on an award with a reported potential end date of January 31, 2027.

Performance period

89.7%

As of Jul 27, 2026Potential end Jan 31, 2027

Current award value as a share of potential value

100.0%

$40.1M current$40.1M potential
Supporting data

Reported performance starts Feb 1, 2022.

No later potential end date is reported; current and potential end dates are both Jan 31, 2027.

$40.1M is obligated against $40.1M in current reported award value (100.0%).

Reported potential end dates: Jan 31, 2023 → Jan 31, 2024 → Jan 31, 2025 → Jan 31, 2026 → Jan 31, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75N93022C00003

PRESIDENT AND FELLOWS OF HARVARD COLLEGE

EO 14398, RFO, INV, NON-COMMERCIAL BOT

$57.3M is obligated on an award with a reported potential end date of March 31, 2027.

Performance period

91.0%

As of Jul 27, 2026Potential end Mar 31, 2027

Current award value as a share of potential value

95.8%

$57.3M current$59.8M potential
Supporting data

Reported performance starts Sep 30, 2019.

No later potential end date is reported; current and potential end dates are both Mar 31, 2027.

$57.3M is obligated against $57.3M in current reported award value (100.0%).

Reported potential end dates: Sep 29, 2026 → Mar 31, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75N93019C00071

CRESTONE, INC.

EO14398 TO PERFORM THE EVALUATION OF SAFETY AND EFFICACY OF CRS3123 TO TREAT CLOSTRIDIUM DIFFICILE INFECTIONS.

$33.3M is obligated on an award with a reported potential end date of January 31, 2027.

Performance period

93.0%

As of Jul 27, 2026Potential end Jan 31, 2027

Current award value as a share of potential value

100.0%

$33.3M current$33.3M potential
Supporting data

Reported performance starts Sep 9, 2019.

No later potential end date is reported; current and potential end dates are both Jan 31, 2027.

$33.3M is obligated against $33.3M in current reported award value (100.0%).

Reported potential end dates: Aug 11, 2023 → Oct 11, 2024 → Jan 31, 2026 → May 31, 2026 → Jan 31, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75N93019C00056

These are research leads, not confirmed recompetes. USAspending records through Jul 27, 2026; reported dates and values can change through later modifications.

Award activity for Research and Development in Biotechnology (except Nanobiotechnology) at the Department of Health and Human Services

Recent contract actions with unusually large obligation changes or meaningful shifts in contractor and funding-office activity.

Base award

This action

+$223.8M

ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)

BARDA - ASPR / DAAPPO / BARDA DCMA

STRATEGIC MARBURG ADVANCED RESEARCH AND DEVELOPMENT, PREPAREDNESS, REGISTRATION, EVALUATION AND PROCUREMENT (SMART-PREP)

Why it stands out

The contractor climbed 7 positions in this market.

It now ranks #1 by positive obligations over the latest 12 months.

Award net obligations
$223.8M
Share of 12-month positive obligations
15.3%
Supporting data
Prime contractor
#1 · 18.2% share
up 7 ranks · +15.0 percentage points · $218.0M net increase; action exceeded it by $5.8M
Funding office
#1 · 78.4% attributed share
$94.5M net decline despite this positive action
Related:Largest share gainUnusually large action
PIID 75A50126C00001
Base award

This action

+$119.2M

SHIONOGI INC

BARDA - ASPR / DAAPPO / BARDA DCMA

LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR THE TREATMENT OF DRUG-RESISTANT SECONDARY BACTERIAL INFECTIONS AND/OR THE TREATMENT OR PEP OF INFECTIONS CAUSED BY BIOTHREAT PATHOGENS.

Why it stands out

No activity for this contractor was reported in this market during the preceding 12 months.

The base action placed the contractor #2 in this market by positive obligations over the latest 12 months.

Award net obligations
$119.2M
Share of 12-month positive obligations
8.2%
Supporting data
Prime contractor
#2 · 8.2% share
Newly active in this market; no actions were reported in the preceding 12 months
Funding office
#1 · 78.4% attributed share
$94.5M net decline despite this positive action
PIID 75A50126C00004
Modification

This action

+$100.5M

START2 GROUP, INC.

BARDA - ASPR / DAAPPO / BARDA DCMA

OTHER TRANSACTION: START2 GROUP, INC. (75A50124C00012)

Why it stands out

This award grew while spending attributed to its office declined.

The modification added $100.5M while office-attributed obligations fell $94.5M overall.

Award net obligations
$151.9M
Share of 12-month positive obligations
6.9%
Supporting data
Prime contractor
#3 · 8.0% share
up 10 ranks · +5.9 percentage points · $84.6M net increase; action exceeded it by $15.9M
Funding office
#1 · 78.4% attributed share
$94.5M net decline despite this positive action
PIID 75A50124C00012 · Mod P00005
Base award

This action

+$58.1M

CIDARA THERAPEUTICS INC

BARDA - ASPR / DAAPPO / BARDA DCMA

DEVELOPMENT OF CD388 AS A LONG-LASTING PROPHYLACTIC ANTI-VIRAL OPTION FOR PROTECTION AGAINST THE HEALTH IMPACTS CAUSED BY INFLUENZA

Why it stands out

No activity for this contractor was reported in this market during the preceding 12 months.

The base action placed the contractor #5 in this market by positive obligations over the latest 12 months.

Award net obligations
$58.1M
Share of 12-month positive obligations
4.0%
Supporting data
Prime contractor
#5 · 4.0% share
Newly active in this market; no actions were reported in the preceding 12 months
Funding office
#1 · 78.4% attributed share
$94.5M net decline despite this positive action
Related:Newly observed contractor cohortLargest newly observed contractor
PIID 75A50125C00017
Modification

This action

+$60.0M

AMGEN USA INC

BARDA - ASPR / DAAPPO / BARDA DCMA

EXERCISE OPTION PERIOD 4 AND MODIFY THE NUMBER OF DOSES. CHANGE THE PERIOD OF PERFORMANCE TO MARCH 4, 2026 THROUGH SEPTEMBER 29, 2032. THE TOTAL CONTRACT FUNDED VALUE INCREASED FROM $713,890,168.42 BY $59,988,838.10 TO $773,879,006.52.

Why it stands out

This award grew while spending attributed to its office declined.

The modification added $60.0M while office-attributed obligations fell $94.5M overall.

Award net obligations
$773.9M
Share of 12-month positive obligations
4.1%
Supporting data
Prime contractor
#4 · 4.1% share
$159.2M net decline despite this positive action
Funding office
#1 · 78.4% attributed share
$94.5M net decline despite this positive action
PIID 75A50122C00065 · Mod P00007
Modification

This action

+$14.8M

PSYCHOGENICS INC.

NATIONAL INSTITUTES OF HEALTH NINDS

SCREENING OF INVESTIGATIONAL AGENTS THROUGH THE NINDS PRECLINICAL SCREENING PLATFORM FOR PAIN (PSPP)

Why it stands out

The contractor climbed 17 positions in this market.

It now ranks #15 by positive obligations over the latest 12 months.

Award net obligations
$36.0M
Share of 12-month positive obligations
1.0%
Supporting data
Funding office
#5 · 1.7% attributed share
up 1 rank · +0.4 percentage points · $2.8M net increase; action exceeded it by $12.0M
PIID 75N95024F00001 · Mod P00002
View recent award activity by date (10)
  1. PRIORITY ONE SERVICES, INC.Deobligation · PIID 75F40123F19001
    Action>−$1
    Award net obligations$2.1M
  2. UNIVERSITY OF HEALTH SCIENCES AND PHARMACY IN ST. LOUISDeobligation · PIID 75F40120C00150
    Action−$2
    Award net obligations$1.2M
  3. ESSENTIAL ACCESS HEALTHModification · PIID 75N94020F00001
    Action+$12K
    Award net obligations$63K
  4. MRIGLOBALDeobligation · PIID 75N93026F00001
    Action−$709K
    Award net obligations$7K
  5. UNIVERSITY OF KENTUCKYDeobligation · PIID 75N94021P00494
    Action−$8K
    Award net obligations$28K
  6. CERUS CORPORATIONModification · PIID 75A50124C00046
    Action+$33.2M
    Award net obligations$65.4M
  7. PRIORITY ONE SERVICES, INC.Deobligation · PIID 75F40123F19003
    Action−$725K
    Award net obligations$4.6M
  8. PHARMACOLOGY DISCOVERY SERVICES TAIWAN, LTD.Base award · PIID 75N93026F00002
    Action+$621K
    Award net obligations$621K
  9. REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THEDeobligation · PIID 75N94021P00706
    Action−$4K
    Award net obligations$15K
  10. PATHCISION MEDICINE, INC.Deobligation · PIID 75N91025C00018
    Action−$55K
    Award net obligations$300K

Apply this research to a live pursuit

Sweetspot connects opportunity qualification, competitive research, capture, and proposal work in one workspace.

See Sweetspot in action

Related market research

Complete market indexes:

Same NAICS at other agencies:

Nearby NAICS at this agency:

Markets sharing leading prime records:

Leading-prime vehicle memberships:

Company memberships do not establish award-channel use.

Reported obligations include contract actions from October 1, 2021 through July 27, 2026. Set-aside and business-size fields reflect award records, not a contractor's current eligibility.

Review data methodology